Basic Information
| LncRNA/CircRNA Name | TP73-AS1 |
| Synonyms | TP73-AS1, KIAA0495, PDAM |
| Region | GRCh38_1:3735601-3747336 |
| Ensemble | ENSG00000227372 |
| Refseq | NR_033708 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | TZM | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | breast cancer tissues, cell lines (Hs578Bst, BT474, MDA-MB-231, T47D, MCF-7, and MDA-MB-453) |
| Expression Pattern | up-regulated |
| Function Description | TP73-AS1 was specifically upregulated in BC tissues and BC cell lines and was correlated to a poorer prognosis in patients with BC. TP73-AS1 could regulate miR-200a through direct targeting. Moreover, TP73-AS1 might compete with TFAM for miR-200a binding thus to promote TFAM expression.TP73-AS1 promoted BC cell proliferation through acting as a competing endogenous RNA (ceRNA) by sponging miR-200a. High TP73-AS1 expression in BC was related with poorer clinicopathological parameters and shorter overall survival. |
| Pubmed ID | 28639399 |
| Year | 2017 |
| Title | TP73-AS1 promotes breast cancer cell proliferation through miR-200a-mediated TFAM inhibition. |
External Links
| Links for TP73-AS1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |